What does this research mean for the field?

GLP-1 receptor agonists influence the risk of colorectal cancer in drug-naive patients with type 2 diabetes compared to non-GLP-1RA antidiabetic medications. Novelty: ClaimNovelty.INCREMENTAL. Consensus alignment: ConsensusAlignment.NEUTRAL.

December 7, 2023Open Access

GLP-1 Receptor Agonists and Colorectal Cancer Risk in Drug-Naive Patients With Type 2 Diabetes, With and Without Overweight/Obesity

Key Points

Key points are not available for this paper at this time.

Abstract

This cohort study compares glucagon-like peptide 1 receptor agonists (GLP-1RAs) with 7 non–GLP-1RA antidiabetics among drug-naive patients with type 2 diabetes.

Bookmark

View Full Paper